查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813886

肝病診斷市場規模、佔有率和趨勢分析報告：按診斷技術、疾病、最終用途、地區和細分市場預測，2025-2033 年

Liver Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnosis Technique, By Disease, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝病診斷市場摘要

預計 2024 年全球肝病診斷市場價值將達到 378.5 億美元，到 2033 年將達到 664 億美元，2025 年至 2033 年的複合年成長率為 6.39%。

這個市場由創新的診斷工具驅動，這些工具能夠早期發現和監測肝病，有助於改善患者的治療效果。

非侵入性檢測方法和分子診斷日益受到重視，這推動了臨床領域的需求。這些診斷解決方案正被用於識別肝纖維化、肝硬化、肝炎和其他肝臟相關疾病。推動這一趨勢的關鍵因素之一是主要企業正加強開發針對特定族群（例如孕婦和愛滋病毒感染者）的高靈敏度、快速檢測方法。此外，旨在建構精準診斷系統的持續研發工作有望帶來及時診斷並改善患者預後。創新診斷方法的採用，以及生活方式的改變（例如增加飲酒量和不良飲食習慣），預計將對肝病診斷市場產生積極影響。

該領域的一項顯著進展是FDA於2024年6月核准了Cepheid的Xpert HCV檢測和GeneXpert Xpress系統。這項批准標誌著首個照護現場，使醫護人員能夠在同一診療過程中診斷和治療C型肝炎。此檢測只需採集指尖血樣，約一小時內即可出結果，並可在多種場所進行，包括物質使用障礙治療機構、懲教機構、注射器服務項目、醫生辦公室、急診科和緊急護理診所。這項進展表明，肝病護理領域正日益趨向於快速、便捷且以患者為中心的診斷解決方案。

生物標記發現和分子診斷技術的進步顯著推動了肝病診斷的發展。次世代定序(NGS) 和液態切片液態生物檢體技術的運用，為臨床醫生提供了更準確、即時的肝病資訊。由於許多肝病通常在無明顯症狀的情況下進展，這些工具能夠更早發現疾病並制定個人化的治療方法。

在全球範圍內，病毒性肝炎、飲酒和非酒精性脂肪性肝病 (NAFLD) 等因素導致的肝病發病率不斷上升，進一步推動了市場的成長。此外，人們對肝臟健康的認知不斷提高，以及政府改善診斷設施的舉措，也大大促進了市場應用的擴展。此外，向門診和就地檢驗的轉變也改善了肝病的可及性，從而可以更快地進行干預，並減輕了醫療保健系統的壓力。

整體而言，肝病診斷市場的技術創新源自於對更快、更準確、侵入性更低的檢測方法的需求。快速照護現場平台和先進分子技術的引入，徹底改變了肝病的檢測和管理方式，使及時干預和個人化治療方案成為可能。此外，人工智慧的整合提升了數據解讀和預測能力，而攜帶式診斷設備則增加了醫療資源匱乏地區的檢測可及性。總而言之，這些技術進步有望改善患者的預後，並塑造市場的未來發展軌跡。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 全球肝病診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場前景。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
  • 全球肝病診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章全球肝病診斷市場：診斷技術評估與趨勢分析

  • 細分儀表板
  • 全球肝病診斷市場診斷技術變化分析
  • 全球肝病診斷市場規模及趨勢分析（依診斷技術，2021-2033 年）
  • 影像
  • 實驗室檢查
  • 內視鏡檢查
  • 切片檢查
  • 其他

第5章全球肝病診斷市場：疾病評估與趨勢分析

  • 細分儀表板
  • 全球肝病診斷市場疾病趨勢分析
  • 全球肝病診斷市場規模及趨勢分析（按疾病，2021-2033 年）
  • NAFLD
  • NASH
  • 纖維化
  • 肝硬化
  • 肝細胞癌
  • 其他

第6章：全球肝病診斷市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球肝病診斷市場最終用途差異分析
  • 全球肝病診斷市場規模與趨勢分析（依最終用途，2021-2033 年）
  • 醫院
  • 研究所
  • 其他

第7章肝病診斷市場：區域估計與趨勢分析

  • 區域儀表板
  • 市場規模、預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 公司/競爭對手分類
  • 戰略地圖
  • 2023年企業市佔率分析
  • 主要認證提供者/計畫所有者列表
  • 公司簡介/上市公司
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Randox Laboratories Ltd
    • Boston Scientific Corporation
    • Laboratory Corporation of America Holdings
    • Fujifilm Corporation
    • Horiba Medical
    • Siemens Healthcare GmbH
    • Quest Diagnostics
Product Code: GVR-4-68038-693-6

Liver Disease Diagnostics Market Summary

The global liver disease diagnostics market size was valued at USD 37.85 billion in 2024 and is expected to reach USD 66.40 billion by 2033, growing at a CAGR of 6.39% from 2025 to 2033. This market centers on innovative diagnostic tools that enable early detection and monitoring of liver conditions, supporting improved patient outcomes.

The growing emphasis on non-invasive testing methods and molecular diagnostics drives demand across clinical settings. These diagnostic solutions find application in identifying liver fibrosis, cirrhosis, hepatitis, and other liver-related disorders. Key contributors to this trend include the intensified efforts by leading companies to develop sensitive and rapid testing methods tailored for specific demographics, such as pregnant women and individuals living with HIV. Additionally, ongoing research and development aimed at creating accurate diagnostic systems is likely to improve timely diagnoses and patient outcomes. The introduction of innovative diagnostic approaches, along with shifts in lifestyle factors like increased alcohol consumption and poor dietary habits, is also projected to influence the liver disease diagnostics market positively.

A notable advancement in this field is the FDA's approval of the Xpert HCV test and GeneXpert Xpress System by Cepheid in June 2024. This authorization marks the first point-of-care hepatitis C RNA test, allowing healthcare providers to diagnose and treat hepatitis C during the same visit. The test provides results in approximately an hour using a fingertip blood sample and can be conducted in various settings, including substance use disorder treatment facilities, correctional facilities, syringe service programs, doctor's offices, emergency departments, and urgent care clinics. This development exemplifies the growing trend toward rapid, accessible, and patient-centered diagnostic solutions in liver disease care.

Advancements in biomarker discovery and molecular diagnostic methods have greatly advanced liver disease diagnostics. The use of next-generation sequencing (NGS) and liquid biopsy techniques offers clinicians more accurate and real-time understanding of liver conditions. These tools enable early detection of disease and personalized treatment approaches, which are vital because many liver disorders often progress without symptoms.

The increasing rate of liver diseases worldwide, caused by factors such as viral hepatitis, alcohol use, and non-alcoholic fatty liver disease (NAFLD), further drives market growth. Greater awareness about liver health and government efforts to improve diagnostic facilities also significantly contribute to broader market adoption. Moreover, the move toward outpatient care and point-of-care testing improves access, allowing for quicker interventions and easing the pressure on healthcare systems.

Overall, innovation in the liver disease diagnostics market is driven by the need for faster, more accurate, and less invasive testing methods. The introduction of rapid point-of-care platforms and advanced molecular techniques has transformed how liver diseases are detected and managed, enabling timely interventions and personalized treatment plans. Additionally, the integration of artificial intelligence is improving data interpretation and predictive capabilities, while portable diagnostic devices are increasing access to testing in underserved areas. These technological advancements collectively contribute to better patient outcomes and are expected to shape the future trajectory of the market.

Global Liver Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global liver disease diagnostics market on the basis of diagnosis technique, disease, end use and region:

  • Diagnosis Technique Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • NAFLD
  • NASH
  • Fibrosis
  • Cirrhosis
  • HCC
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Diagnosis Technique Segment
    • 1.2.2. Disease Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Global Liver Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Liver Diseases
      • 3.2.1.2. Advancements in Diagnostic Technologies
      • 3.2.1.3. Increasing Awareness and Early Detection
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Advanced Diagnostics
      • 3.2.2.2. Limited Awareness in Developing Regions
    • 3.2.3. Market opportunity analysis
  • 3.3. Global Liver Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Global Liver Disease Diagnostics Market: Diagnosis Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Liver Disease Diagnostics Market Diagnosis Technique Movement Analysis
  • 4.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Diagnosis Technique, 2021 to 2033 (USD Million)
  • 4.4. Imaging
    • 4.4.1. Imaging market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Laboratory Tests
    • 4.5.1. Laboratory Tests market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Endoscopy
    • 4.6.1. Endoscopy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Biopsy
    • 4.7.1. Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Liver Disease Diagnostics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Liver Disease Diagnostics Market Disease Movement Analysis
  • 5.3. Global Liver Disease Diagnostics Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. NAFLD
    • 5.4.1. NAFLD market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. NASH
    • 5.5.1. NASH market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Fibrosis
    • 5.6.1. Fibrosis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Cirrhosis
    • 5.7.1. Cirrhosis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.8. HCC
    • 5.8.1. HCC market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Liver Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Liver Disease Diagnostics Market End Use Movement Analysis
    • 6.2.1. Global Liver Disease Diagnostics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4. Laboratories
    • 6.4.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Liver Disease Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Share Analysis, 2023
  • 8.4. List of Key Certification Providers/Scheme Owners
  • 8.5. Company Profiles/Listing
    • 8.5.1. Abbott
      • 8.5.1.1. Company overview
      • 8.5.1.2. Financial performance
      • 8.5.1.3. Product benchmarking
      • 8.5.1.4. Strategic initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd.
      • 8.5.2.1. Company overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Product benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. Thermo Fisher Scientific Inc.
      • 8.5.3.1. Company overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Product benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. Randox Laboratories Ltd
      • 8.5.4.1. Company overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Product benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. Boston Scientific Corporation
      • 8.5.5.1. Company overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Product benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Laboratory Corporation of America Holdings
      • 8.5.6.1. Company overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Product benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. Fujifilm Corporation
      • 8.5.7.1. Company overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Product benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Horiba Medical
      • 8.5.8.1. Company overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Product benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Siemens Healthcare GmbH
      • 8.5.9.1. Company overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Product benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Quest Diagnostics
      • 8.5.10.1. Company overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Product benchmarking
      • 8.5.10.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviation
  • Table 3. U.S. Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 4. U.S. Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 5. U.S. Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 6. North America Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 7. North America Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 8. North America Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 9. North America Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 10. Canada Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 11. Canada Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 12. Canada Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 13. Mexico Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 14. Mexico Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 15. Mexico Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 16. Europe Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 17. Europe Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 18. Europe Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 19. Europe Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 20. UK Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 21. UK Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 22. UK Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 23. Germany Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 24. Germany Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 25. Germany Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 26. France Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 27. France Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 28. France Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 29. Italy Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 30. Italy Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 31. Italy Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 32. Spain Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 33. Spain Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 34. Spain Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 35. Denmark Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 36. Denmark Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 37. Denmark Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 38. Sweden Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 39. Sweden Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 40. Sweden Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 41. Norway Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 42. Norway Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 43. Norway Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 44. Asia Pacific Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 45. Asia Pacific Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 46. Asia Pacific Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 47. Asia Pacific Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 48. Japan Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 49. Japan Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 50. Japan Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 51. China Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 52. China Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 53. China Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 54. India Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 55. India Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 56. India Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 57. Australia Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 58. Australia Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 59. Australia Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 60. South Korea Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 61. South Korea Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 62. South Korea Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 63. Thailand Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 64. Thailand Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 65. Thailand Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 66. Latin America Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 67. Latin America Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 68. Latin America Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 69. Latin America Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 70. Brazil Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 71. Brazil Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 72. Brazil Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 73. Argentina Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 74. Argentina Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 75. Argentina Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 76. MEA Liver Disease Diagnostics market, by region, 2021 to 2033 (USD Million)
  • Table 77. MEA Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 78. MEA Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 79. MEA Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 80. South Africa Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 81. South Africa Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 82. South Africa Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 83. Saudi Arabia Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 84. Saudi Arabia Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 85. Saudi Arabia Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)
  • Table 86. UAE Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 87. UAE Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 88. Kuwait Liver Disease Diagnostics market, by diagnosis technique, 2021 to 2033 (USD Million)
  • Table 89. Kuwait Liver Disease Diagnostics market, by disease, 2021 to 2033 (USD Million)
  • Table 90. Kuwait Liver Disease Diagnostics market, by end use, 2021 to 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Liver disease diagnostics: Market outlook
  • Fig. 9 Liver disease diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Liver disease diagnostics market driver impact
  • Fig. 15 Liver disease diagnostics market restraint impact
  • Fig. 16 Liver disease diagnostics market strategic initiatives analysis
  • Fig. 17 Liver disease diagnostics market: disease movement analysis
  • Fig. 18 Liver disease diagnostics market: disease outlook and key takeaways
  • Fig. 19 NAFLD market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 20 NASH market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 21 Fibrosis market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 22 Cirrhosis market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 23 HCC market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 25 Liver disease diagnostics market: Diagnosis technique movement analysis
  • Fig. 26 Liver disease diagnostics market: Diagnosis technique outlook and key takeaways
  • Fig. 27 Imaging market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 28 Laboratory tests market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 29 Endoscopy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 30 Biopsy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 32 Liver disease diagnostics market: End use movement analysis
  • Fig. 33 Liver disease diagnostics market: End use outlook and key takeaways
  • Fig. 34 Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 35 Laboratories market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 37 Global liver disease diagnostics market: Regional movement analysis
  • Fig. 38 Global liver disease diagnostics market: Regional outlook and key takeaways
  • Fig. 39 North America market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 40 US market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 41 Canada market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 42 Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 44 UK market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 45 Germany market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 46 France market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 47 Italy market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 48 Spain market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 49 Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 50 Norway market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 51 Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 53 Japan market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 54 China market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 55 India market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 56 Australia market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 57 Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 58 South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 59 Latin America market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 60 Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 61 Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 62 Middle East and Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 64 South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 65 UAE market estimates and forecasts, 2021 to 2033 (USD Million)
  • Fig. 66 Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)